Motility, Biofilm Formation and Antimicrobial Efflux of Sessile and Planktonic Cells of Achromobacter xylosoxidans.
Signe M NielsenLine N PenstoftNiels Nørskov LauritsenPublished in: Pathogens (Basel, Switzerland) (2019)
Achromobacter xylosoxidans is an innately multidrug-resistant bacterium capable of forming biofilms in the respiratory tract of cystic fibrosis (CF) patients. During the transition from the planktonic stage to biofilm growth, bacteria undergo a transcriptionally regulated differentiation. An isolate of A. xylosoxidans cultured from the sputum of a CF patient was separated into sessile and planktonic stages in vitro, and the transcriptomes were compared. The selected genes of interest were subsequently inactivated, and flagellar motility was found to be decisive for biofilm formation in vitro. The spectrum of a new resistance-nodulation-cell division (RND)-type multidrug efflux pump (AxyEF-OprN) was characterized by inactivation of the membrane fusion protein. AxyEF-OprN is capable of extruding some fluoroquinolones (levofloxacin and ciprofloxacin), tetracyclines (doxycycline and tigecycline) and carpabenems (ertapenem and imipenem), which are classes of antimicrobials that are widely used for treatment of CF pulmonary infections.
Keyphrases
- biofilm formation
- cystic fibrosis
- pseudomonas aeruginosa
- acinetobacter baumannii
- respiratory tract
- staphylococcus aureus
- candida albicans
- lung function
- multidrug resistant
- end stage renal disease
- single cell
- newly diagnosed
- induced apoptosis
- escherichia coli
- drug resistant
- chronic kidney disease
- cell therapy
- genome wide
- klebsiella pneumoniae
- endothelial cells
- prognostic factors
- case report
- bone marrow
- stem cells
- gene expression
- patient reported outcomes
- mesenchymal stem cells
- cell death
- combination therapy
- pulmonary tuberculosis
- chronic obstructive pulmonary disease
- patient reported
- replacement therapy